BENDHEIM JACK 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) 10% Owner Jack Bendheim Sells 72,198 Shares
What Happened
Jack Bendheim, a director, officer and 10% owner of Phibro Animal Health Corp (PAHC), sold a total of 72,198 shares in open-market transactions on Feb 10–11, 2026 for aggregate gross proceeds of approximately $3,737,711. The reported disposals (weighted-average prices shown) were:
- 50,994 shares @ $51.76 = $2,639,271
- 7,020 shares @ $52.17 = $366,254
- 13,950 shares @ $51.61 = $719,969
- 234 shares @ $52.21 = $12,217
These were sales (not purchases) — typically viewed as routine cashing-out rather than a bullish signal.
Key Details
- Transaction dates: Feb 10, 2026 and Feb 11, 2026. Filing date: Feb 11, 2026 (timely).
- Total shares sold: 72,198; total proceeds: ~$3.74 million. Individual weighted-average prices listed above.
- The filing notes several weighted-average price ranges (sales occurred in multiple trades); the reporting person will provide per-price breakdowns on request.
- Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
- Many of the reported securities are directly held by BFI, which Mr. Bendheim controls; he disclaims beneficial ownership of those shares except for any pecuniary interest. A small lot is reported as directly held by Mr. Bendheim.
- Shares owned after the transactions are not specified in the provided extract — see the full Form 4 for exact post-transaction holdings.
Context
- These were pre-planned sales under a 10b5-1 plan (common for insiders to schedule dispositions). For retail investors, purchases tend to be more informative of insider conviction; routine plan-based sales are often for portfolio/tax/liquidity reasons.
- As a 10% owner and controller of BFI, Bendheim’s transactions reflect institutional/owner-level dispositions rather than an ordinary employee sale.
Insider Transaction Report
Form 4
BENDHEIM JACK
DirectorPresident and CEO10% Owner
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-02-10$51.76/sh−50,994$2,639,271→ 71,964 total(indirect: See) - Sale
Class A Common Stock
[F1][F4][F3]2026-02-10$52.17/sh−7,020$366,254→ 64,944 total(indirect: See) - Sale
Class A Common Stock
[F1][F5][F3]2026-02-11$51.61/sh−13,950$719,969→ 50,994 total(indirect: See) - Sale
Class A Common Stock
[F1][F6][F3]2026-02-11$52.21/sh−234$12,217→ 50,760 total(indirect: See)
Holdings
- 16,840
Class A Common Stock
[F7]
Footnotes (7)
- [F1]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.10 to $52.09. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5 and 6.
- [F3]The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.10 to $52.30.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.11 to $52.04.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.205 to $52.21.
- [F7]The reported securities are directly held by Jack Bendheim.